File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Ataxia–Telangiectasia Mutated (ATM) Protein Expression in Uterine Smooth Muscle Tumors

TitleAtaxia–Telangiectasia Mutated (ATM) Protein Expression in Uterine Smooth Muscle Tumors
Authors
Issue Date2020
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/modpathol/
Citation
109th Annual Meeting of the United States and Canadian Academy of Pathology (USCAP 2020): Eyes on you - Gynecologic and Obstetric Pathology (1047-1234), Los Angeles, CA, 29 February - 5 March 2020. In Modern Pathology, 2020, v. 33 n. suppl. 2, p. 1094, abstract no. 1142 How to Cite?
AbstractBackground: Ataxia-telangiectasia-mutated (ATM) is a serine-threonine protein kinase essential in cellular response to double-strand DNA damage. It undergoes auto- phosphorylation after DNA damage and subsequently initiates a signalling cascade that involves the phosphorylation of several other substrates, many of which play an important tumor-suppressing role. When ATM is functional, cells can respond to stress using this DNA damage response pathway. Dysregulation of this pathway in uterine leiomyosarcoma contributes to genomic instability. Analysis of ATM protein expression in uterine smooth muscle tumors has not been investigated. Design: Expression of ATM and phosphorylated ATM (p-ATM) was evaluated on 69 uterine leiomyosarcomas, 18 leiomyomas and 28 myometrium. Immunohistochemistry was performed with monoclonal antibodies for ATM (Clone Y170, Abcam) and p-ATM (Clone EP1890Y, Abcam) on formalin-fixed paraffin embedded tissue. Staining of the nucleus was considered positive. Lymphocytes served as internal positive controls. Immunohistochemical expression was analysed by using a histoscore, generated by multiplying the intensity (0, 1, 2, 3) with the extent (0, 10%, 25%, 50%, 75% and 100%). The final score ranged from 0 to 300, with 0 indicated complete loss of expression. Results: The median age of leiomyosarcoma patients was 50 years (range 33–80). All patients underwent hysterectomy with bilateral salpingo-oophorectomy and without preoperative chemo or radiation therapy. All tumors showed spindle cells differentiation, with diffuse nuclear atypia and >10 mitoses per 10 high power fields (0.55 mm field diameter). Tumor cell necrosis was present in 46 (70%). Abnormal expression (reduced or loss of expression) of either marker was observed in 65/69 (94%) leiomyosarcomas. In 42 (60.9%), there was a complete loss of staining. The remaining cases had a range of histoscores which ranged from 0 – 300 (Table 1). Retained expression of both markers were present in both the leiomyoma and myometrium groups. There was a significant difference in ATM and p-ATM expression between myometrium and leiomyosarcoma (p<0.05), and between leiomyoma and leiomyosarcoma (p<0.05). Follow-up information was obtained for 65 cases, which ranged from 1 to 276 months (median, 26 months). Forty patients (61.2%) died of disease and two (3%) were alive with disease. Among the group of leiomyosarcoma patients who had tumors which showed complete loss of expression of either ATM, p-ATM, or both markers, 28 (71.8%) either died of disease or alive with disease at last follow-up (p<0.05). Conclusions: • Abnormal expression of ATM or p-ATM was present in 94% of leiomyosarcoma, with complete loss of expression of either one or both markers in 60.9%, reflecting the frequent dysregulation of DNA damage response. • Retained expression of ATM and p-ATM was observed in leiomyoma and myometrium. • Within the leiomyosarcoma group, although the majority had complete loss of expression in either or both markers, the remaining tumors expressed ATM and p-ATM at various intensities and extents. Therefore, they were not found be robust diagnostic markers for distinguishing benign and malignant tumors. • Loss of expression of either ATM, p-ATM, or both markers, was a poor prognostic factor in our cohort.
DescriptionDOI, Scupus ID and PMID link to supplement: Abstracts from USCAP 2020: Gynecologic and Obstetric Pathology (1047-1234)
Persistent Identifierhttp://hdl.handle.net/10722/288206
ISSN
2021 Impact Factor: 8.209
2020 SCImago Journal Rankings: 2.596

 

DC FieldValueLanguage
dc.contributor.authorLee, HHY-
dc.contributor.authorChow, KL-
dc.contributor.authorWong, HS-
dc.contributor.authorChong, TY-
dc.contributor.authorTse, KY-
dc.contributor.authorIp, P-
dc.date.accessioned2020-10-05T12:09:25Z-
dc.date.available2020-10-05T12:09:25Z-
dc.date.issued2020-
dc.identifier.citation109th Annual Meeting of the United States and Canadian Academy of Pathology (USCAP 2020): Eyes on you - Gynecologic and Obstetric Pathology (1047-1234), Los Angeles, CA, 29 February - 5 March 2020. In Modern Pathology, 2020, v. 33 n. suppl. 2, p. 1094, abstract no. 1142-
dc.identifier.issn0893-3952-
dc.identifier.urihttp://hdl.handle.net/10722/288206-
dc.descriptionDOI, Scupus ID and PMID link to supplement: Abstracts from USCAP 2020: Gynecologic and Obstetric Pathology (1047-1234)-
dc.description.abstractBackground: Ataxia-telangiectasia-mutated (ATM) is a serine-threonine protein kinase essential in cellular response to double-strand DNA damage. It undergoes auto- phosphorylation after DNA damage and subsequently initiates a signalling cascade that involves the phosphorylation of several other substrates, many of which play an important tumor-suppressing role. When ATM is functional, cells can respond to stress using this DNA damage response pathway. Dysregulation of this pathway in uterine leiomyosarcoma contributes to genomic instability. Analysis of ATM protein expression in uterine smooth muscle tumors has not been investigated. Design: Expression of ATM and phosphorylated ATM (p-ATM) was evaluated on 69 uterine leiomyosarcomas, 18 leiomyomas and 28 myometrium. Immunohistochemistry was performed with monoclonal antibodies for ATM (Clone Y170, Abcam) and p-ATM (Clone EP1890Y, Abcam) on formalin-fixed paraffin embedded tissue. Staining of the nucleus was considered positive. Lymphocytes served as internal positive controls. Immunohistochemical expression was analysed by using a histoscore, generated by multiplying the intensity (0, 1, 2, 3) with the extent (0, 10%, 25%, 50%, 75% and 100%). The final score ranged from 0 to 300, with 0 indicated complete loss of expression. Results: The median age of leiomyosarcoma patients was 50 years (range 33–80). All patients underwent hysterectomy with bilateral salpingo-oophorectomy and without preoperative chemo or radiation therapy. All tumors showed spindle cells differentiation, with diffuse nuclear atypia and >10 mitoses per 10 high power fields (0.55 mm field diameter). Tumor cell necrosis was present in 46 (70%). Abnormal expression (reduced or loss of expression) of either marker was observed in 65/69 (94%) leiomyosarcomas. In 42 (60.9%), there was a complete loss of staining. The remaining cases had a range of histoscores which ranged from 0 – 300 (Table 1). Retained expression of both markers were present in both the leiomyoma and myometrium groups. There was a significant difference in ATM and p-ATM expression between myometrium and leiomyosarcoma (p<0.05), and between leiomyoma and leiomyosarcoma (p<0.05). Follow-up information was obtained for 65 cases, which ranged from 1 to 276 months (median, 26 months). Forty patients (61.2%) died of disease and two (3%) were alive with disease. Among the group of leiomyosarcoma patients who had tumors which showed complete loss of expression of either ATM, p-ATM, or both markers, 28 (71.8%) either died of disease or alive with disease at last follow-up (p<0.05). Conclusions: • Abnormal expression of ATM or p-ATM was present in 94% of leiomyosarcoma, with complete loss of expression of either one or both markers in 60.9%, reflecting the frequent dysregulation of DNA damage response. • Retained expression of ATM and p-ATM was observed in leiomyoma and myometrium. • Within the leiomyosarcoma group, although the majority had complete loss of expression in either or both markers, the remaining tumors expressed ATM and p-ATM at various intensities and extents. Therefore, they were not found be robust diagnostic markers for distinguishing benign and malignant tumors. • Loss of expression of either ATM, p-ATM, or both markers, was a poor prognostic factor in our cohort.-
dc.languageeng-
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/modpathol/-
dc.relation.ispartofModern Pathology-
dc.titleAtaxia–Telangiectasia Mutated (ATM) Protein Expression in Uterine Smooth Muscle Tumors-
dc.typeConference_Paper-
dc.identifier.emailLee, HHY: horlee@hku.hk-
dc.identifier.emailChow, KL: cklpatho@hku.hk-
dc.identifier.emailTse, KY: tseky@hku.hk-
dc.identifier.emailIp, P: philipip@hku.hk-
dc.identifier.authorityTse, KY=rp02391-
dc.identifier.authorityIp, P=rp01890-
dc.description.natureabstract-
dc.identifier.pmid32139817-
dc.identifier.scopuseid_2-s2.0-85081529098-
dc.identifier.hkuros314956-
dc.identifier.volume33-
dc.identifier.issuesuppl. 2-
dc.identifier.spage1094, abstract no. 1142-
dc.identifier.epage1094, abstract no. 1142-
dc.publisher.placeUnited Kingdom-
dc.identifier.partofdoi10.1038/s41379-020-0473-8-
dc.identifier.issnl0893-3952-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats